Marco Antonio Briones-Orta

Marco Antonio Briones-Orta

Auto-generated profile, based on publicly available information

Marco Antonio Briones-Orta

Regeneration and Repair, Institute of Hepatology, Foundation for Liver Research, London, United Kingdom

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
MBMarco Antonio Briones-Orta
Marco Antonio Briones-Orta
SAS. Eréndira Avendaño-Vázquez
S. Eréndira Avendaño-Vázquez
DADiana I. Aparicio-Bautista
Diana I. Aparicio-Bautista
JCJason Coombes
Jason Coombes
GWGeorg F. Weber
Georg F. Weber
WSWING-KIN SYN
WING-KIN SYN

5 June 2014 in Gut
Verified
Journal Article
Closed access
PDF file
JCJason Coombes
Jason Coombes
MSM Swiderska-Syn
M Swiderska-Syn
LDL Dollé
L Dollé
DRD Reid
D Reid
BEB Eksteen
B Eksteen
WSWING-KIN SYN
WING-KIN SYN
Background Chronic liver injury triggers a progenitor cell repair response, and liver fibrosis occurs when repair becomes deregulated. Previously, we reported that reactivation of the hedgehog pathway promotes fibrogenic liver repair. Osteopontin (OPN) is a hedgehog-target, and a cytokine that is highly upregulated in fibrotic tissues, and regulates stem-cell fate. Thus, we hypothesised that OPN may modulate liver progenitor cell response, and thereby, modulate fibrotic outcomes. We further evaluated the impact of OPN-neutralisation on murine liver fibrosis. Methods Liver progenitors (603B and bipotential mouse oval liver) were treated with OPN-neutralising aptamers in the presence or absence of transforming growth factor (TGF)-β, to determine if (and how) OPN modulates liver progenitor function. Effects of OPN-neutralisation (using OPN-aptamers or OPN-neutralising antibodies) on liver progenitor cell response and fibrogenesis were assessed in three models of liver fibrosis (carbon tetrachloride, methionine-choline deficient diet, 3,5,-diethoxycarbonyl-1,4-dihydrocollidine diet) by quantitative real time (qRT) PCR, Sirius-Red staining, hydroxyproline assay, and semiquantitative double-immunohistochemistry. Finally, OPN expression and liver progenitor response were corroborated in liver tissues obtained from patients with chronic liver disease. Results OPN is overexpressed by liver progenitors in humans and mice. In cultured progenitors, OPN enhances viability and wound healing by modulating TGF-β signalling. In vivo, OPN-neutralisation attenuates the liver progenitor cell response, reverses epithelial-mesenchymal-transition in Sox9+ cells, and abrogates liver fibrogenesis. Conclusions OPN upregulation during liver injury is a conserved repair response, and influences liver progenitor cell function. OPN-neutralisation abrogates the liver progenitor cell response and fibrogenesis in mouse models of liver fibrosis.

1 January 2016 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
JCJason Coombes
Jason Coombes
SCSteve S. Choi
Steve S. Choi
MSMarzena Swiderska-Syn
Marzena Swiderska-Syn
PMPaul Manka
Paul Manka
DRDanielle T. Reid
Danielle T. Reid
WSWING-KIN SYN
WING-KIN SYN

14 March 2013 in Cancer Research
Verified
Journal Article
Open access
PDF file
MBMarco A. Briones-Orta
Marco A. Briones-Orta
LLLaurence Levy
Laurence Levy
CMChris D. Madsen
Chris D. Madsen
DDDebipriya Das
Debipriya Das
YEYigit Erker
Yigit Erker
CHCaroline S. Hill
Caroline S. Hill
TGF-β can act as a tumor suppressor at early stages of cancer progression and as a tumor promoter at later stages. The E3 ubiquitin ligase Arkadia (RNF111) is a critical component of the TGF-β signaling pathway, being required for a subset of responses, those mediated by Smad3–Smad4 complexes. It acts by mediating ligand-induced degradation of Ski and SnoN (SKIL), which are 2 potent transcriptional repressors. Here, we investigate the role of Arkadia in cancer using model systems to address both potential tumor-suppressive and tumor-promoting roles. Stable reexpression of Arkadia in lung carcinoma NCI-H460 cells, which we show contain a hemizygous nonsense mutation in the Arkadia/RNF111 gene, efficiently restored TGF-β–induced Smad3-dependent transcription, and substantially decreased the ability of these cells to grow in soft agar in vitro. However, it had no effect on tumor growth in vivo in mouse models. Moreover, loss of Arkadia in cancer cell lines and human tumors is rare, arguing against a prominent tumor-suppressive role. In contrast, we have uncovered a potent tumor-promoting function for Arkadia. Using 3 different cancer cell lines whose tumorigenic properties are driven by TGF-β signaling, we show that loss of Arkadia function, either by overexpression of dominant negative Arkadia or by siRNA-induced knockdown, substantially inhibited lung colonization in tail vein injection experiments in immunodeficient mice. Our findings indicate that Arkadia is not critical for regulating tumor growth per se, but is required for the early stages of cancer cell colonization at the sites of metastasis. Cancer Res; 73(6); 1800–10. ©2012 AACR.

1 February 2018 in The American Journal of the Medical Sciences
Verified
Journal Article
Open access
KMKosha J. Mehta
Kosha J. Mehta
JCJason D. Coombes
Jason D. Coombes
MBMarco Briones-Orta
Marco Briones-Orta
PMPaul P. Manka
Paul P. Manka
RWRoger Williams
Roger Williams
WSWING-KIN SYN
WING-KIN SYN
Although excess iron induces oxidative stress in the liver, it is unclear whether it directly activates the hepatic stellate cells (HSC). We evaluated the effects of excess iron on fibrogenesis and transforming growth factor beta (TGF-β) signaling in murine HSC. Cells were treated with holotransferrin (0.005-5g/L) for 24 hours, with or without the iron chelator deferoxamine (10µM). Gene expressions (α-SMA, Col1-α1, Serpine-1, TGF-β, Hif1-α, Tfrc and Slc40a1) were analyzed by quantitative real time-polymerase chain reaction, whereas TfR1, ferroportin, ferritin, vimentin, collagen, TGF-β RII and phospho-Smad2 proteins were evaluated by immunofluorescence, Western blot and enzyme-linked immunosorbent assay. HSC expressed the iron-uptake protein transferrin receptor 1 (TfR1) and the iron-export protein ferroportin. Holotransferrin upregulated TfR1 expression by 1.8-fold (P < 0.03) and ferritin accumulation (iron storage) by 2-fold (P < 0.01), and activated HSC with 2-fold elevations (P < 0.03) in α-SMA messenger RNA and collagen secretion, and a 1.6-fold increase (P < 0.01) in vimentin protein. Moreover, holotransferrin activated the TGF-β pathway with TGF-β messenger RNA elevated 1.6-fold (P = 0.05), and protein levels of TGF-β RII and phospho-Smad2 increased by 1.8-fold (P < 0.01) and 1.6-fold (P < 0.01), respectively. In contrast, iron chelation decreased ferritin levels by 30% (P < 0.03), inhibited collagen secretion by 60% (P < 0.01), repressed fibrogenic genes α-SMA (0.2-fold; P < 0.05) and TGF-β (0.4-fold; P < 0.01) and reduced levels of TGF-β RII and phospho-Smad2 proteins. HSC express iron-transport proteins. Holotransferrin (iron) activates HSC fibrogenesis and the TGF-β pathway, whereas iron depletion by chelation reverses this, suggesting that this could be a useful adjunct therapy for patients with fibrosis. Further studies in primary human HSC and animal models are necessary to confirm this.

3 May 2011 in Liver International
Verified
Journal Article
Closed access
PDF file
BDBlanca Delgado-Coello
Blanca Delgado-Coello
MBMarco A. Briones‐Orta
Marco A. Briones‐Orta
MMMarina Macías‐Silva
Marina Macías‐Silva
JMJaime Mas-Oliva
Jaime Mas-Oliva